Chemical Property of Brexpiprazole
Chemical Property:
- Melting Point:179 - 181oC
- Boiling Point:675.2±55.0 °C(Predicted)
- PKA:11.22±0.70(Predicted)
- Density:1.245±0.06 g/cm3(Predicted)
- Storage Temp.:Refrigerator
- Solubility.:Dichloromethane (Slightly), Chloroform (Slightly), Methanol (Slightly)
- XLogP3:4.7
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:7
- Exact Mass:433.18239829
- Heavy Atom Count:31
- Complexity:636
- Purity/Quality:
-
99% *data from raw suppliers
Brexpiprazole *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Antipsychotic Agents
- Canonical SMILES:C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4
- Recent ClinicalTrials:Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD
- Recent EU Clinical Trials:A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder
- Recent NIPH Clinical Trials:A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
-
Description
Brexpiprazole is a kind of atypical antipsychotic. It is a dopamine D2 receptor partial agonist. As a novel serotonin-dopamine activity modulator, it can be used for the treatment of schizophrenia, and for the adjunctive treatment for depression. It can also provide efficacy and tolerability over established adjunctive treatments formajor depressive disorder(MDD).Recent study has also suggested it can ameliorate PCP-induced cognitive deficits in mice via 5-HT1A receptors. Brexpiprazole is a novel
antipsychotic drug which serves as a serotonin ? dopamine
activity modulator and has demonstrated efficacy as an
adjunctive treatment in patients with major depressive disorder
(MDD). The drug exhibits a unique pharmacological profile,
acting as a partial agonist of serotonin 5-HT1A and dopamine
D2 receptors and as a full antagonist of 5-HT2A and
noradrenaline α1B/2C receptors, with similar subnanomolar
binding affinity. The drug, which was developed by Otsuka
and Lundbeck, was approved in 2015 by the FDA for the
treatment of schizophrenia and as an adjunctive treatment for
depression. Brexpiprazole is widely considered to be a
successor to Otsuka’s antipsychotic drug aripiprazole (trade
name Abilify) whose patent expired in August 2014.
-
Uses
Brexpiprazole is a drug candidate useful in treatment and prevention of mental disorders including CNS disorders.
